Immunity to melanoma antigens: from self-tolerance to immunotherapy
/in International Publications, Malignant Melanoma /von 2006-01-01 / Adv. Immunol. 2006;90:243-95Vaccine efficacy of fusogenic liposomes containing tumor cell-lysate against murine B16BL6 melanoma
/in International Publications, Malignant Melanoma /von 2006-01-01 / Biol. Pharm. Bull. 2006 Jan;29(1):100-4Immunotherapy for prostate cancer
/in International Publications, Prostate Cancer /von 2006-01-01 / Curr. Pharm. Des. 2006;12(7):807-17Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2006-01-01 / Cytotherapy 2006;8(3):277-89Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2006-01-01 / Leuk. Lymphoma 2006 Jan;47(1):29-37Quick generation of fully mature dendritic cells from monocytes with OK432, low-dose prostanoid, and interferon-alpha as potent immune enhancers
/in Gastric Cancer, International Publications /von 2006-01-01 / J. Immunother. 2006 Jan-Feb;29(1):67-77Intrahepatic cholangiocarcinoma with lymph node metastasis successfully treated by immunotherapy with CD3-activated T cells and dendritic cells after surgery: report of a case
/in Gallbladder Cancer, International Publications /von 2006-01-01 / Surg. Today 2006;36(6):559-62Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3
/in Chronic Virus Hepatitis, International Publications /von 2006-01-01 / J. Gen. Virol. 2006 Jan;87(Pt 1):1-10Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96
/in International Publications, Malignant Lymphoma /von 2005-12-15 / Clin. Cancer Res. 2005 Dec;11(24 Pt 1):8808-15IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de